This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (73)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alan L. Robin, MD

Arch Ophthalmol. 1988;106(7):912-915.

Abstract
• A prospective, double-masked, randomized study evaluated the effects of unilateral therapy with topical 1% apraclonidine hydrochloride (aplonidine hydrochloride or ALO 2145) in 20 normal volunteers. No medications were applied to either eye during the control day. Following baseline measurements on the day of treatment, one drop of topical 1% apraclonidine hydrochloride was placed on one eye and a placebo (vehicle) was placed on the fellow eye. Intraocular pressure (IOP) measurements, pupil size, blood pressure, and pulse rate were assessed on both days at the baseline and 1, 3, 5, and 7 hours later. The 1% apraclonidine hydrochloride lowered the mean IOP ( ± SD) a maximum of 6.5 ± 4.3 mm Hg (37.3% ± 20.4%) from the baseline on the day of treatment. A statistically significant 2.7 ± 3.4-mm Hg (14.9% ± 19.0%) mean IOP decrease from the baseline was noted in the contralateral placebo-treated eye. No significant changes in the coefficient of outflow, blood pressure, or heart rate were noted. Eyelid retraction, conjunctival blanching, and mydriasis were frequently noted in eyes treated with 1% apraclonidine hydrochloride.

Author Affiliations
From the Glaucoma Services, Sinai Hospital of Baltimore; and The Wilmer Ophthalmological Institute, The Johns Hopkins Hospital, Baltimore.

Footnotes
Accepted for publication Jan 8, 1988.

Reprint requests to The Wilmer Institute, Maumenee Bldg, Room B-117, The Johns Hopkins Hospital, 600 N Wolfe St, Baltimore, MD 21205 (Dr Robin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The sensitivity and specificity of 0.5% apraclonidine in the diagnosis of oculosympathetic paresis
Koc et al.
Br J Ophthalmol 2005;89:1442-1444.
ABSTRACT | FULL TEXT  

Ocular Effects of Apraclonidine in Horner Syndrome
Morales et al.
Arch Ophthalmol 2000;118:951-954.
ABSTRACT | FULL TEXT  

The teardrop sign: a rare dermatological reaction to brimonidine
SCRUGGS et al.
Br J Ophthalmol 2000;84:667e-667.
FULL TEXT  

Effects of 0.5% apraclonidine on optic nerve head and peripapillary retinal blood flow
Kim and Kim
Br J Ophthalmol 1997;81:1070-1072.
ABSTRACT | FULL TEXT  

A 1-Year Study of Brimonidine Twice Daily in Glaucoma and Ocular Hypertension: A Controlled, Randomized, Multicenter Clinical Trial
Schuman et al.
Arch Ophthalmol 1997;115:847-852.
ABSTRACT  

Questions Concerning the Role of Apraclonidine in the Management of Glaucoma
Robin
Arch Ophthalmol 1995;113:712-714.
ABSTRACT  

Clinical Experience With the Long-term Use of 1% Apraclonidine: Incidence of Allergic Reactions
Butler et al.
Arch Ophthalmol 1995;113:293-296.
ABSTRACT  

Brimonidine in the Prevention of Intraocular Pressure Elevation Following Argon Laser Trabeculoplasty
David et al.
Arch Ophthalmol 1993;111:1387-1390.
ABSTRACT  

Effect of Oxymetazoline on Aqueous Humor Dynamics and Ocular Blood Flow in Monkeys and Rabbits
Wang et al.
Arch Ophthalmol 1993;111:535-538.
ABSTRACT  

Effects of Topical Flurbiprofen on the Intraocular Pressure Lowering Effects of Apraclonidine and Timolol
Sulewski et al.
Arch Ophthalmol 1991;109:807-809.
ABSTRACT  

Cardiovascular and Intraocular Pressure Effects and Plasma Concentrations of Apraclonidine
Coleman et al.
Arch Ophthalmol 1990;108:1264-1267.
ABSTRACT  

The Effects of Apraclonidine on Conjunctival Oxygen Tension
Serdahl et al.
Arch Ophthalmol 1989;107:1777-1779.
ABSTRACT  

Apraclonidine: A One-Week Dose-Response Study
Jampel et al.
Arch Ophthalmol 1988;106:1069-1073.
ABSTRACT